Table 3.
Effects of AMG on the evaluation of neurotransmitters level in PPA-treated autistic rats.
| Neurotransmitters Levels | ||||
|---|---|---|---|---|
| Groups | 5-HT (ng/mg Protein) |
Glutamate (ng/mg Protein) |
Dopamine (ng/mg Protein) |
Ach (ng/mg Protein) |
| Vehicle Control | 36.63 ± 0.55 | 103.66 ± 0.57 | 85.48 ± 0.34 | 9.48 ± 0.26 |
| Sham Control | 37.57 ± 0.63 | 103.52 ± 0.38 | 87.54 ± 0.54 | 9.49 ± 0.36 |
| AMG200 per se | 36.72 ± 0.59 | 101.52 ± 0.47 | 85.35 ± 0.60 | 9.49 ± 0.26 |
| PPA | 12.81 ± 0.52 * | 278.90 ± 0.58 * | 29.36 ± 0.55 * | 0.80 ± 0.01 * |
| PPA + AMG100 | 15.51 ± 0.60 @ | 201.82 ± 0.60 @ | 44.48 ± 0.52 @ | 5.71 ± 0.61 @ |
| PPA + AMG200 | 18.29 ± 0.59 @# | 172.34 ± 0.59 @# | 48.85 ± 0.56 @# | 7.18 ± 0.37 @# |
Statistical analysis followed by one-way ANOVA (post-hoc Tukey’s test), * p < 0.05 v/s vehicle control; sham control and AMG200 per se; @ p<0.05 v/s PPA; @# p<0.05 v/s PPA + AMG100; (n = 6 rats per group).